Stem-cell cancer treatment developer Vor Biopharma has collected more capital from investors including existing backers Johnson & Johnson and PureTech Health.
US-based cancer treatment developer Vor Biopharma completed a $110m series B round yesterday that included medical group Johnson & Johnson and pharmaceutical firm PureTech Health.
Investment manager RA Capital Management led the round, which included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as investment and financial services group Fidelity.
Osage University Partners (OUP), Pagliuca Family Office and 5AM Ventures also participated in the round along with unnamed…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
